Yahoo Finance • 2 months ago
Wondering what's happening in Friday's pre-market session? Find an overview in this article. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT EEIQ [https://www.chartmill.com/stock/quote/EEIQ/profile] 127.0% EPICQUEST... Full story
Yahoo Finance • 2 months ago
LA PALMA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced plans for a strateg... Full story
Yahoo Finance • 3 months ago
LA PALMA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced it has entered into... Full story
Yahoo Finance • 3 months ago
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT LIDR [https://www.chartmill.com/st... Full story
Yahoo Finance • 3 months ago
[Glowing dollar symbol, cryptocurrency network, neon green dollar symbol, blue blockchain links, futuristic finance tech, global economy, cyberpunk aesthetic. 3D render.] * Liminatus Pharma (NASDAQ:LIMN [https://seekingalpha.com/symbol/... Full story
Yahoo Finance • 3 months ago
Liminatus Pharma, Inc. (LIMN) announced it has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies in its treasury management framework. The preclinical-stage biopharmaceutical company, w... Full story
Yahoo Finance • 3 months ago
LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that it has initiat... Full story
Yahoo Finance • 3 months ago
Liminatus Pharma, Inc. (NASDAQ:LIMN), a $173 million market cap pharmaceutical company, announced Thursday that its board of directors has expanded to six members with the appointment of Philip Lemons and Richard Baek as directors, effecti... Full story
Yahoo Finance • 3 months ago
Liminatus Pharma, Inc. (NASDAQ:LIMN), a $245 million market cap biotech company whose stock has declined nearly 47% in the past week, announced Wednesday that it has entered into a memorandum of understanding to form a research and develop... Full story
Yahoo Finance • 4 months ago
[A graph moving up] Richard Drury * Liminatus Pharma (NASDAQ:LIMN [https://seekingalpha.com/symbol/LIMN]) shares rose after the company said it regained compliance with Nasdaq's listing needs [https://seekingalpha.com/filing/10070728].... Full story